Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Optic pathway glioma (OPG) is a benign tumor that develop along the optic nerve (chiasm, tracts, and radiations) characterized by impairment or loss of vision and may be accompanied by diencephalic symptoms such as reduced growth and alteration in sleeping patterns. OPG are often linked to neurofibromatosis type 1 (NF1).
Biomarker and diagnostic research for optic pathway glioma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
4 clinical trials registered. Interventions under study include drug therapy, procedural interventions, and other interventions. Pipeline includes 1 PHASE3, 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
121 publications have been identified in PubMed for optic pathway glioma. Research spans Review / Meta-Analysis (22%), Case Report / Case Series (21%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:01 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 25 | 21% |
Disease patterns and progression | 22 | 18% |
Laboratory research | 14 | 12% |
Testing and diagnosis research | 13 | 11% |
Clinical study results | 13 | 11% |
New treatment approaches | 5 | 4% |
Other research | 2 | 2% |
Brown J (2026). [PMID: 41708157](https://pubmed.ncbi.nlm.nih.gov/41708157/). *Operative neurosurgery (Hagerstown, Md.)*. [Clinical Trial Publication]
O'Connor D (2026). [PMID: 42073553](https://pubmed.ncbi.nlm.nih.gov/42073553/). *Cancers (Basel)*. [Review / Meta-Analysis]
Al Hassan S (2026). [PMID: 41290115](https://pubmed.ncbi.nlm.nih.gov/41290115/). *American journal of ophthalmology*. [Gene Therapy / Novel Therapeutics]
Tea HRH (2026). [PMID: 41870104](https://pubmed.ncbi.nlm.nih.gov/41870104/). *Int Ophthalmol Clin*. [Review / Meta-Analysis]
Nakano Y (2026). [PMID: 41911600](https://pubmed.ncbi.nlm.nih.gov/41911600/). *J Neurosurg Case Lessons*. [Gene Therapy / Novel Therapeutics]
Unknown (2026). [PMID: 39879649](https://pubmed.ncbi.nlm.nih.gov/39879649/). *Neuro Oncol*. [Other]
Kokossis D (2026). [PMID: 41856269](https://pubmed.ncbi.nlm.nih.gov/41856269/). *J Pediatr*. [Epidemiology / Natural History]
Ziafati M (2026). [PMID: 42053615](https://pubmed.ncbi.nlm.nih.gov/42053615/). *Graefes Arch Clin Exp Ophthalmol*. [Review / Meta-Analysis]
Hall WA (2026). [PMID: 32809418](https://pubmed.ncbi.nlm.nih.gov/32809418/). *Unknown Journal*. [Diagnostic / Biomarker]
Alshehri A (2026). [PMID: 42150614](https://pubmed.ncbi.nlm.nih.gov/42150614/). *Can J Ophthalmol*. [Diagnostic / Biomarker]
AI-curated news mentioning optic pathway glioma
Updated Aug 25, 2026
A new study presents a self-assembled nano-multiple warheads platform designed for precise targeting in combinatorial chemotherapy, photothermal therapy (PTT), and photodynamic therapy (PDT) against glioma. This innovative approach could enhance treatment efficacy for patients with this challenging brain tumor.
The National Cancer Institute is offering licenses for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H. These cell lines, derived from the same patient pre- and post-malignant transformation, present a unique opportunity for research into glioma progression and treatment resistance.
A study evaluates the effectiveness of integrated (18)F-FET PET/MR fusion for preoperative assessment of IDH status in adult glioma. The research compares various fusion algorithms, potentially enhancing diagnostic accuracy for glioma patients.
A recent study highlights the varying prevalence of optic pathway gliomas in children diagnosed with neurofibromatosis type 1. This research contributes to understanding the relationship between these conditions and may inform future clinical approaches.